Puma Biotechnology 745867AX9 Bond
| PBYI Stock | USD 3.14 0.12 3.97% |
Puma Biotechnology has over 111.49 Million in debt which may indicate that it relies heavily on debt financing. As of now, Puma Biotechnology's Net Debt To EBITDA is decreasing as compared to previous years. The Puma Biotechnology's current Debt To Equity is estimated to increase to 2.05, while Long Term Debt is projected to decrease to under 54.2 M. With a high degree of financial leverage come high-interest payments, which usually reduce Puma Biotechnology's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Puma Biotechnology's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Puma Biotechnology's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Puma Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Puma Biotechnology's stakeholders.
For most companies, including Puma Biotechnology, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Puma Biotechnology, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Puma Biotechnology's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 2.0716 | Book Value 1.449 | Operating Margin 0.2741 | Profit Margin 0.0954 | Return On Assets 0.0973 |
Puma |
Given the importance of Puma Biotechnology's capital structure, the first step in the capital decision process is for the management of Puma Biotechnology to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Puma Biotechnology to issue bonds at a reasonable cost.
| Popular Name | Puma Biotechnology PulteGroup 5 percent |
| Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
| Equity ISIN Code | US74587V1070 |
| Bond Issue ISIN Code | US745867AX94 |
| S&P Rating | Others |
| Maturity Date | 15th of January 2027 |
| Issuance Date | 29th of July 2016 |
| Coupon | 5.0 % |
Puma Biotechnology Outstanding Bond Obligations
| Boeing Co 2196 | US097023DG73 | Details | |
| HSBC Holdings PLC | US404280DR76 | Details | |
| PulteGroup 6 percent | US745867AT82 | Details | |
| PulteGroup 55 percent | US745867AW12 | Details | |
| PulteGroup 5 percent | US745867AX94 | Details | |
| PulteGroup 7875 percent | US745867AM30 | Details | |
| PulteGroup 6375 percent | US745867AP60 | Details | |
| MGM Resorts International | US552953CD18 | Details | |
| AerCap Global Aviation | US00773HAA59 | Details |
Understaning Puma Biotechnology Use of Financial Leverage
Understanding the composition and structure of Puma Biotechnology's debt gives an idea of how risky is the capital structure of the business and if it is worth investing in it. The degree of Puma Biotechnology's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Net Debt | 26.9 M | 28.3 M | |
| Long Term Debt | 65.7 M | 54.2 M | |
| Short and Long Term Debt Total | 111.5 M | 123.2 M | |
| Long Term Debt Total | 111.7 M | 104.8 M | |
| Short and Long Term Debt | 30.6 M | 25.8 M | |
| Short Term Debt | 43.6 M | 45.8 M | |
| Net Debt To EBITDA | 0.57 | 0.59 | |
| Debt To Equity | 1.95 | 2.05 | |
| Interest Debt Per Share | 2.50 | 2.62 | |
| Debt To Assets | 0.45 | 0.35 | |
| Long Term Debt To Capitalization | 0.55 | 0.64 | |
| Total Debt To Capitalization | 0.66 | 0.66 | |
| Debt Equity Ratio | 1.95 | 2.05 | |
| Debt Ratio | 0.45 | 0.35 | |
| Cash Flow To Debt Ratio | 0.26 | 0.27 |
Currently Active Assets on Macroaxis
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:Check out the analysis of Puma Biotechnology Fundamentals Over Time. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.417 | Earnings Share 0.47 | Revenue Per Share 5.045 | Quarterly Revenue Growth 0.435 | Return On Assets 0.0973 |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.